Hepatocellular carcinoma: Novel molecular targets in carcinogenesis for future therapies

Gaetano Bertino, Shirin Demma, Annalisa Ardiri, Maria Proiti, Salvatore Gruttadauria, Adriana Toro, Giulia Malaguarnera, Nicoletta Bertino, Michele Malaguarnera, Mariano Malaguarnera, Isidoro Di Carlo

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background. Hepatocellular carcinoma is one of the most common and lethal malignant tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled. Due to late diagnosis and/or advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefit are available in up to 70% of patients. During the last decades, no effective conventional cytotoxic systemic therapy was available contributing to the dismal prognosis in patients with HCC. A better knowledge of molecular hepatocarcinogenesis provides today the opportunity for targeted therapy. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: "hepatocellular carcinoma," "molecular hepatocarcinogenesis," "targeted therapy," and "immunotherapy." Discussion and Conclusion. Treatment decisions are complex and dependent upon tumor staging, presence of portal hypertension, and the underlying degree of liver dysfunction. The knowledge of molecular hepatocarcinogenesis broadened the horizon for patients with advanced HCC. During the last years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.

Original languageEnglish
Article number203693
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Tumors
Hepatocellular Carcinoma
Carcinogenesis
Liver
T-cells
Immunotherapy
Modulators
Molecular Targeted Therapy
Therapeutics
Vaccines
Neoplasms
Neoplasm Staging
Delayed Diagnosis
Portal Hypertension
PubMed
Liver Cirrhosis
Liver Diseases
Clinical Trials
Databases
T-Lymphocytes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Hepatocellular carcinoma : Novel molecular targets in carcinogenesis for future therapies. / Bertino, Gaetano; Demma, Shirin; Ardiri, Annalisa; Proiti, Maria; Gruttadauria, Salvatore; Toro, Adriana; Malaguarnera, Giulia; Bertino, Nicoletta; Malaguarnera, Michele; Malaguarnera, Mariano; Di Carlo, Isidoro.

In: BioMed Research International, Vol. 2014, 203693, 2014.

Research output: Contribution to journalArticle

Bertino, G, Demma, S, Ardiri, A, Proiti, M, Gruttadauria, S, Toro, A, Malaguarnera, G, Bertino, N, Malaguarnera, M, Malaguarnera, M & Di Carlo, I 2014, 'Hepatocellular carcinoma: Novel molecular targets in carcinogenesis for future therapies', BioMed Research International, vol. 2014, 203693. https://doi.org/10.1155/2014/203693
Bertino, Gaetano ; Demma, Shirin ; Ardiri, Annalisa ; Proiti, Maria ; Gruttadauria, Salvatore ; Toro, Adriana ; Malaguarnera, Giulia ; Bertino, Nicoletta ; Malaguarnera, Michele ; Malaguarnera, Mariano ; Di Carlo, Isidoro. / Hepatocellular carcinoma : Novel molecular targets in carcinogenesis for future therapies. In: BioMed Research International. 2014 ; Vol. 2014.
@article{049b913a1eee4e73ae443a49331b95f8,
title = "Hepatocellular carcinoma: Novel molecular targets in carcinogenesis for future therapies",
abstract = "Background. Hepatocellular carcinoma is one of the most common and lethal malignant tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled. Due to late diagnosis and/or advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefit are available in up to 70{\%} of patients. During the last decades, no effective conventional cytotoxic systemic therapy was available contributing to the dismal prognosis in patients with HCC. A better knowledge of molecular hepatocarcinogenesis provides today the opportunity for targeted therapy. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: {"}hepatocellular carcinoma,{"} {"}molecular hepatocarcinogenesis,{"} {"}targeted therapy,{"} and {"}immunotherapy.{"} Discussion and Conclusion. Treatment decisions are complex and dependent upon tumor staging, presence of portal hypertension, and the underlying degree of liver dysfunction. The knowledge of molecular hepatocarcinogenesis broadened the horizon for patients with advanced HCC. During the last years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.",
author = "Gaetano Bertino and Shirin Demma and Annalisa Ardiri and Maria Proiti and Salvatore Gruttadauria and Adriana Toro and Giulia Malaguarnera and Nicoletta Bertino and Michele Malaguarnera and Mariano Malaguarnera and {Di Carlo}, Isidoro",
year = "2014",
doi = "10.1155/2014/203693",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Hepatocellular carcinoma

T2 - Novel molecular targets in carcinogenesis for future therapies

AU - Bertino, Gaetano

AU - Demma, Shirin

AU - Ardiri, Annalisa

AU - Proiti, Maria

AU - Gruttadauria, Salvatore

AU - Toro, Adriana

AU - Malaguarnera, Giulia

AU - Bertino, Nicoletta

AU - Malaguarnera, Michele

AU - Malaguarnera, Mariano

AU - Di Carlo, Isidoro

PY - 2014

Y1 - 2014

N2 - Background. Hepatocellular carcinoma is one of the most common and lethal malignant tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled. Due to late diagnosis and/or advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefit are available in up to 70% of patients. During the last decades, no effective conventional cytotoxic systemic therapy was available contributing to the dismal prognosis in patients with HCC. A better knowledge of molecular hepatocarcinogenesis provides today the opportunity for targeted therapy. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: "hepatocellular carcinoma," "molecular hepatocarcinogenesis," "targeted therapy," and "immunotherapy." Discussion and Conclusion. Treatment decisions are complex and dependent upon tumor staging, presence of portal hypertension, and the underlying degree of liver dysfunction. The knowledge of molecular hepatocarcinogenesis broadened the horizon for patients with advanced HCC. During the last years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.

AB - Background. Hepatocellular carcinoma is one of the most common and lethal malignant tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled. Due to late diagnosis and/or advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefit are available in up to 70% of patients. During the last decades, no effective conventional cytotoxic systemic therapy was available contributing to the dismal prognosis in patients with HCC. A better knowledge of molecular hepatocarcinogenesis provides today the opportunity for targeted therapy. Materials and Methods. A search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: "hepatocellular carcinoma," "molecular hepatocarcinogenesis," "targeted therapy," and "immunotherapy." Discussion and Conclusion. Treatment decisions are complex and dependent upon tumor staging, presence of portal hypertension, and the underlying degree of liver dysfunction. The knowledge of molecular hepatocarcinogenesis broadened the horizon for patients with advanced HCC. During the last years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.

UR - http://www.scopus.com/inward/record.url?scp=84903835849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903835849&partnerID=8YFLogxK

U2 - 10.1155/2014/203693

DO - 10.1155/2014/203693

M3 - Article

C2 - 25089265

AN - SCOPUS:84903835849

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 203693

ER -